Evaluation of the effectiveness of magnesium compared with sodium valporate in migraine headache prophylaxis

Vice chancellor for research, Qom University of Medical Sciences0 个研究点目标入组 228 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•All patients diagnosed with migraine according to the latest International Headache Society criteria; history of migraine with or without aura for at least 6 months; patient’s age between 18-65 years; at least 2 attacks monthly.
•Exclusion criteria: non-migraine headaches (total number of headache days per month more than 15); overuse of analgesics in migraine attacks (consumption of ergots, NSAIDs and triptans more than 8 days a month); substance and alcohol dependence; illiteracy of patients and their family (unable to fill diaries); pregnancy and breast feeding; any previous history of magnesium or sodium valporate intolerance; history of renal, liver and chronic disease; elevated liver enzymes in the first sampling more than 2 times the normal; neurologic disorders other than migraine; use of supplements that contain magnesium, calcium and riboflavin; use of herbal anti-migraine; use of anti-depressant and anti-psychotic medications.

发起方

Vice chancellor for research, Qom University of Medical Sciences